2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6113 Real world optimization of label-free subcellular spatial biochemical profiling in acute leukemia: A proof of principle feasibility demonstration

Yingjie Lai, N/A, Yaocheng Xia2, Sila Usta, MS3, Signy Chow, MD, FRCPC4, Hubert Tsui, MD, PhD5, Chenxi Qian, PhD6
1 Sunnybrook Research Institue, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 Sunnybrook Research Institue, Toronto, Ontario, Canada
3 Sunnybrook Research Institue, Toronto, Ontario, Canada
4 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, Sunnybrook Research Institue, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 Ontario Institute for Cancer Research, Toronto, Ontario, Canada, Sunnybrook Research Institue, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Introduction: The diagnosis and optimal management of acute leukemia (AL) is dependent on rapid laboratory techniques which conventionally include morphology, immunophenotyping, cytogenetics, and various molecular techniques. AL classification and access to targeted therapy are increasingly dependent on genomic biomarkers. Genomic abnormalities however are a surrogate measure of perturbed metabolic pathophysiology and closely related to drug resistance and susceptibilities for which current clinical laboratory standard of care approaches do not assess. Stimulated Raman scattering microscopy (SRSM) provides rapid, label-free imaging of endogenous molecular vibrations with subcellular resolution at a single cell level. We envision SRSM technology to be able to evaluate the biochemical spatial landscape within individual blasts, providing a potential platform for advancing blast characterization beyond lineage assignment by flow cytometry and conventional genomic-limited AL stratification. We herein explore the feasibility of deploying SRSM technology using fresh blood from suspected AL presentations at a tertiary AL referral centre.

Methods:
Suspected AL patients were identified upon referral to the Complex Malignant Hematology Program at Sunnybrook Health Sciences Centre. In the peri-AL diagnostic stage, patients were consented to the Sunnybrook Hematology Biobank. Peripheral blood collected in EDTA was subjected to iterative methodological approaches in order to determine pre-analytical variables that affected SRSM image quality. Following an optimization period of 3 months, a standardized workflow was established to assess the ability of SRSM to delineate blasts from other leukocytes and begin distinguishing blasts by lineage based solely on SRSM constructed image features. Conventional Wright-Giemsa based morphology, complete blood count (CBC) differentials, clinical flow cytometry and final hematopathology classification based on clinical genomic reports were used for gold standard/ground truth benchmarking.  

Results: We developed a feasible workflow that analyzes surplus clinical unstained blood smear samples from AL patients without destructive sample processing. Our automatic SRSM imaging program identifies leukocytes and selectively acquires high resolution single cell images for downstream spatial biochemical analysis. SRSM image channels associated with CH2, CH3, and nucleic acids were combined to generate image contrast analogous to Wright-Giemsa-stained blood smears, enabling corollary blast identification by hematopathologists. In the latest formulation, we asked if SRSM image analysis could distinguish a series of three live AL presentations for which the lineage and final classification were unknown at the time of SRSM imaging. Our explainable image analysis pipeline extracted single-cell spatial biochemical features, aggregated them at the patient level, and identified distinct biochemical profiles through hierarchical clustering. These profiles reflected whole-cell changes in saturated and unsaturated lipid, protein, nucleic acids, cytochrome c, heme, and subcellular biochemical organization. Remarkably, the current pipeline separated the case of B-lymphoblast-dominant mixed phenotype acute leukemia with B-monocytic features from two cases of acute myeloid leukemia (AML). It further identified a strong promyelocyte metabolic profile corresponding to a presentation of acute promyelocytic leukemia with PML::RARA vs AML with mutated NPM1. These findings indicate that spatial biochemical profiling provides unique information and it can be incorporated into clinical workflow by using unstained blood smears. It provides proof of principle for SRSM as a feasible method for biochemical evaluation of AL using real-world clinically sourced specimens. As we expand the cohort, we envision SRSM to predict AL lineage and genomic subcategories of AL including potentially unique unexpected metabolic vulnerabilities that would support the use of genomically “off label” targeted therapies.

Yingjie Lai, N/A: No relevant conflicts of interest to declare.